



MANGALAM DRUGS AND ORGANICS LTD

A. Audited Financial Results for the Quarter and Year ended 31st March 2014

(Rs. in Lacs)

Sr. No.	Particulars	Audited (Refer Note-2)	Unaudited		Audited	Audited
		Quarter ended			Year ended	Year Ended
		3 months ended 31.3.14	Previous 3 months ended in the current year 31.12.13	Correspondi ng 3months ended in the previous year 31.03.13	Current accounting year ended 31.03.14	Previous accounting year ended 31.03.13
1	Sales/Income from operation(Net of Excise duty)	3777.48	3806.34	4590.55	12231.97	12525.87
2	Other Operating Income	14.93	3.31	26.67	35.78	104.31
3	Total Net Income from Operation	3792.41	3809.65	4617.22	12267.75	12630.18
4	Expenditure					
	(a) Increase / decrease in stock in trade & work in progress	(434.77)	391.21	1307.55	(544.63)	2005.28
	(b) Consumption of raw materials	2772.57	2027.58	2711.32	8374.88	8104.06
	(c) Employees Cost	224.30	289.18	261.41	1024.55	946.32
	(d) Depreciation	101.43	102.34	100.62	401.05	393.97
	(e) Other expenditure	621.54	722.87	437.34	2436.55	1911.19
	(f) Total	3285.07	3533.18	4818.24	11692.40	13360.82
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	507.34	276.47	(201.02)	575.35	(730.64)
6	Other income	2.46	3.79	50.86	8.23	52.96
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	509.80	280.26	(150.16)	583.58	(677.68)
8	Finance Cost	206.94	290.28	253.20	974.21	1002.24
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	302.86	(10.02)	(403.36)	(390.63)	(1679.92)
10	Exceptional Items	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	302.86	(10.02)	(403.36)	(390.63)	(1679.92)
12	Tax Expenses(incl Deferred Tax)	(86.71)	0.00	(499.98)	(86.71)	(499.98)
13	Net Profit(+)/Loss(-) after Tax (11-12)	389.57	(10.02)	96.62	(303.92)	(1179.94)
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	389.57	(10.02)	96.62	(303.92)	(1179.94)
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	1004.47		1308.39	1004.47	1308.39
18	Earning per share (EPS)					
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.96	(0.07)	0.73	(2.31)	(8.96)
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	2.96	(0.07)	0.73	(2.31)	(8.96)
19	Non Promoters Shareholding					
	- Number of shares	7628115	7602453	7548453	7628115	7548453
	- Percentage of shareholding	57.88	57.69	57.28	57.88	57.28
20	Promoters and Promoter group Shareholding					
	a) Pledged/ Encumbered					
	Number of Shares	5491228	5467708	5448708	5491228	5448708
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	98.94	98.06	96.78	98.94	96.78
	Percentage of Shares (as a % of the total share capital of the company)	41.67	41.49	41.35	41.67	41.35
	b) Non-encumbered					
	Number of Shares	58905	108087	181087	58905	181087
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	1.06	1.94	3.22	1.06	3.22
	Percentage of Shares (as a % of the total share capital of the company)	0.45	0.82	1.37	0.45	1.37

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 29th, May 2014
- The results for the quarter ended March 31, 2014 are derived figures arrived at by subtracting the results for the nine months ended on December 31, 2013 from the audited results for the year ended March 31, 2014.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk drugs" the disclosure requirement of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- During the Quarter & Year ended 31st March 2014, 0 Investor complaint were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 29.05.2014

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

Director
(Shri Govardhan M. Dhoot)